Table 1.
Baseline characteristics of the patients.
| Characteristic | Group A Pediatric patients with IST + EPAG (n = 15) | Group B Pediatric patients with IST only (n = 45) | P |
|---|---|---|---|
| Gender (male/female) | 10/5 | 26/19 | 0.543 |
| Age at treatment (years) | |||
| Median (range) | 13 (4∼18) | 13 (7-17) | 0.700 |
| Severity of aplastic anemia, n (%) | 1.000 | ||
| SAA | 6 (40) | 20 (44.4) | |
| VSAA | 9 (60.0) | 25 (55.6) | |
| History(months) | |||
| Median (range) | 1.0 (0.1-8.0) | 1.0 (0.2-120.0) | 0.567 |
| Baseline laboratory values, median (interquartile range) | |||
| Reticulocyte count (×109/L) | 9.2 (3.60-31.60) | 7.20 (4.15-18.10) | 0.484 |
| Neutrophil count (×109/L) | 0.24 (0.06-0.57) | 0.18 (0.04∼0.40) | 0.393 |
| Lymphocyte count (×109/L) | 1.64 (0.73∼2.62) | 1.43 (0.44-2.03) | 0.398 |
| Platelet count (×109/L) | 5 (3∼13) | 9 (6-14) | 0.364 |
| Hemoglobin (g/L) | 66 (55∼83) | 61 (55-67) | 0.206 |
| Ferritin (ng/ml) | |||
| Median (range) | 279.8 (149.8∼2009.0) | 360.7 (1.6∼2398.0) | 0.645 |
| PNH clones, n (%) | 3 (20.0) | 4 (8.9) | 0.351 |
| Treatment of IST, n (%) | 0.516 | ||
| rATG + CsA | 5 (33.3) | 11 (24.4) | |
| pALG + CsA | 10 (66.7) | 34 (75.6) | |
| HSCT after IST, n (%) | 1.000 | ||
| Yes | 2 (13.3) | 5 (11.1) | |
| No | 13 (86.7) | 40 (88.9) | |
| Time between IST onset and EPAG initiation (days) | |||
| Median (range) | 0 (-4∼60) | N/A | N/A |
| EPAG duration (months) | |||
| Median (range) | 7.10 (3.33∼22.30) | N/A | N/A |
| Follow∼up (months) | |||
| Median (range) | 19 (7∼34) | 74 (1-119) | <0.001 |
Note: IST, immunosuppressive therapy; EPAG, eltrombopag; SAA, severe aplastic anemia; VSAA, very severe aplastic anemia; PNH, paroxysmal nocturnal hemoglobinuria; CsA, cyclosporine; r-ATG, rabbit-antithymocyte globulin; p-ALG, porcine-lymphocyte globulin; HSCT, hematopoietic stem cell transplantation N/A, not available.